Quantcast

Method of using cyclooxygenase-2 inhibitors in the treatment and prevention of neoplasia

Imported: 23 Feb '17 | Published: 22 Oct '02

Karen Seibert, Jaime Masferrer, Gary B Gordon

USPTO - Utility Patents

Abstract

This invention relates to the use of cyclooxygenase-2 inhibitors or derivatives thereof in preventing and treating neoplasia. In particular, the invention describes the method of preventing and treating epithelial cell neoplasia in a subject, said method comprising treating the subject with a therapeutically-effective amount of a compound of Formula I.

wherein A, R

2 and R

3 are as described in the specification.

Claims

1. A method of treating a neoplasia in a subject in need of such treatment, said method comprising treating the subject with a therapeutically-effective amount of a compound of Formula II

or a pharmaceutically acceptable salt thereof wherein

2. The method of claim 1 wherein the neoplasia is selected from the group consisting of colorectal cancer, gastrointestinal cancer, liver cancer, bladder cancer, cervical cancer, prostate cancer, lung cancer, breast cancer and skin cancer.

3. A method of claim 1, wherein the neoplasia is adenomatous polyps.

4. A method of treating a subject suffering from a neoplastic disease state with a conjunctive therapy, said method comprising treating the subject with a therapeutically-effective amount of a cyclooxygenase-2 selective compound and a compound selected from the group consisting of antibiotic agents, alkylating agents, antimetabolite agents, hormonal agents, immunological agents, interferon agents, metallomatrix proteases (MMP) inhibitors, SOD, and

v

3 inhibitors, wherein the selective COX-2 inhibitor is a compound of formula II or formula III

or a pharmaceutically acceptable salt thereof wherein

5. The method of claim 4 wherein the compound is selected from compounds, and their pharmaceutically acceptable salts, of the group consisting of

6. The method of claim 5 wherein the compound is selected from compounds, and their pharmaceutically acceptable salts, of the group consisting of

7. A method of treating a neoplasia in a subject in need of such treatment, said method comprising treating the subject with a therapeutically-effective amount of a compound of the formula

or a pharmaceutically acceptable salt thereof wherein

8. The method of claim 7 wherein the compound is selected from compounds, and their pharmaceutically acceptable salts, of the group consisting of

9. The method of claim 7 wherein the compound is selected from compounds, and their pharmaceutically acceptable salts, of the group consisting of

10. A method of treating familial adenomatous polyps in a subject in need of such treatment, said method comprising administering to the subject a therepeutically-effective amount of a compound which is 4-5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide.

11. A method of treating familial adenomatous polyps in a subject in need of such treatment, said method comprising admistering to the subject a pharmaceutical composition comprising 4-5-(4-methylphenyl)-3-(trifluoromethyl)-1H-pyrazol-1-yl)benzenesulfonamide together with a pharmaceutically acceptable carrier.

12. A method according to claim 11, wherein the carrier comprises lactose, magnesium stearate, and gelatin.